John Mendelsohn

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Targeting the epidermal growth factor receptor for cancer therapy
    John Mendelsohn
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:1S-13S. 2002
  2. pmc From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway
    Marina Cardo-Vila
    David H Koch Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 107:5118-23. 2010
  3. doi request reprint Personalizing oncology: perspectives and prospects
    John Mendelsohn
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 491, Houston, TX 77030 4009, USA
    J Clin Oncol 31:1904-11. 2013
  4. doi request reprint A national cancer clinical trials system for targeted therapies
    John Mendelsohn
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Sci Transl Med 3:75cm8. 2011
  5. ncbi request reprint Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
    John Mendelsohn
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030 4009, USA
    J Clin Oncol 21:2787-99. 2003
  6. ncbi request reprint Epidermal growth factor receptor targeting in cancer
    John Mendelsohn
    The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 33:369-85. 2006
  7. doi request reprint Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
    Xinqun Li
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Unit 036, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1207-17. 2008
  8. ncbi request reprint Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab
    Yang Lu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:8240-7. 2007
  9. pmc Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation
    Ke Liang
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 18:423-35. 2010
  10. ncbi request reprint The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression
    Rodney B Luwor
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Oncogene 24:4433-41. 2005

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Targeting the epidermal growth factor receptor for cancer therapy
    John Mendelsohn
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:1S-13S. 2002
  2. pmc From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway
    Marina Cardo-Vila
    David H Koch Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 107:5118-23. 2010
    ..Finally, a synthetic retro-inverted derivative, (D)(CARVC), became our preclinical prototype of choice. This study reveals an EGFR-decoy drug candidate with translational potential...
  3. doi request reprint Personalizing oncology: perspectives and prospects
    John Mendelsohn
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 491, Houston, TX 77030 4009, USA
    J Clin Oncol 31:1904-11. 2013
    ....
  4. doi request reprint A national cancer clinical trials system for targeted therapies
    John Mendelsohn
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Sci Transl Med 3:75cm8. 2011
    ..The result will be more rapid translation of recent scientific advances into increased benefits for patients with cancer...
  5. ncbi request reprint Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
    John Mendelsohn
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030 4009, USA
    J Clin Oncol 21:2787-99. 2003
    ..Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clinical development strategies...
  6. ncbi request reprint Epidermal growth factor receptor targeting in cancer
    John Mendelsohn
    The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 33:369-85. 2006
    ..Major efforts are, belatedly, attempting to identify molecular markers that can predict patients more likely to respond to anti-EGFR therapy...
  7. doi request reprint Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab
    Xinqun Li
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Unit 036, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1207-17. 2008
    ....
  8. ncbi request reprint Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab
    Yang Lu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:8240-7. 2007
    ....
  9. pmc Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation
    Ke Liang
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 18:423-35. 2010
    ....
  10. ncbi request reprint The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression
    Rodney B Luwor
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Oncogene 24:4433-41. 2005
    ....
  11. doi request reprint Building a personalized medicine infrastructure at a major cancer center
    Funda Meric-Bernstam
    University of Texas MD Anderson Cancer Center, 1400 Pressler St, FCT17 5030, Houston, TX 77030, USA
    J Clin Oncol 31:1849-57. 2013
    ..This article will focus on the challenges and opportunities that accompany the building of infrastructure for personalized cancer therapy...
  12. pmc Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?
    Massimo Cristofanilli
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 103:17073-4. 2006
  13. ncbi request reprint Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic
    John Mendelsohn
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Immunol Immunother 52:342-6. 2003
  14. pmc Bioinformatics and systems biology
    Prahlad T Ram
    Department of Systems Biology, Institute for Personalized Cancer Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX 77054, USA
    Mol Oncol 6:147-54. 2012
    ..With this data in hand, the challenge from the bioinformatics and systems biology point of view is how does one convert data into information and knowledge that can improve the delivery of personalized therapy to the patient...
  15. ncbi request reprint HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
    Christiane Knuefermann
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
    Oncogene 22:3205-12. 2003
    ....
  16. ncbi request reprint The role of growth factor signaling in malignancy
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Treat Res 115:19-72. 2003